Genetic News and Research

RSS

Researchers discover genomic characteristics that define testicular germ cell cancer

Testicular germ cell cancer, a disease that is rare but growing in incidence in men in the United States, is considered to be among the most curable of solid tumors. Now researchers from the University of North Carolina Lineberger Comprehensive Cancer Center and a consortium of institutions have discovered the genetic and genomic characteristics that define the disease.

12 Jun 2018

Scientists discover first genetic marker for bone tumor

The first genetic marker for the bone tumor, osteoblastoma, has been discovered by scientists at the Wellcome Sanger Institute and their collaborators.

12 Jun 2018

Research identifies new genetic variations that could indicate higher prostate cancer risk

As the result of a six-year long research process, Fredrick R. Schumacher, PhD, a cancer epidemiology researcher at Case Western Reserve University School of Medicine, and an international team of more than 100 colleagues have identified 63 new genetic variations that could indicate higher risk of prostate cancer in men of European descent.

12 Jun 2018

Immune response in RA patients linked to inflammation and joint damage

To diagnose rheumatoid arthritis, antibodies to the amino acid citrulline are commonly measured. A new study from Uppsala University shows that a broad mix of different antibodies in the joints is the dominant factor that can be associated with severe inflammation and joint damage.

12 Jun 2018

New blood test better than having a needle inserted into the eye

People diagnosed with a deadly form of cancer will no longer face the prospect of having a needle inserted into their eye thanks to a new blood test developed by Edith Cowan University researchers.

12 Jun 2018

Study shows how to slow down spread of Ebola virus

Between 2013 and 2016, West Africa suffered the most severe outbreak of Ebola ever recorded. In Guinea, Sierra Leone and Liberia, a total of 29,000 patients were diagnosed with the disease. More than 11,000 people didn't survive.

12 Jun 2018

New research explores why minority children have worse cancer outcomes

New research will focus on finding better treatments for minority children with high-risk cancer malignancies - a group whose outcomes and survival rates are worse than other pediatric patients.

11 Jun 2018

Scientists pinpoint potential treatment target for pediatric liver cancer

A protein in the cell nucleus already targeted therapeutically for several types of cancer has now been linked to an aggressive form of pediatric liver cancer called hepatoblastoma (HBL), according to a study published in the Nature journal Communications Biology.

11 Jun 2018

Synthetic gene reveals potential therapeutic target for rare, inherited disease

DNA Repair is essential for a healthy organism. In every day of our lives, tens of thousands of damages occur in the genetic material of our cells. Hence, it is not surprising that a broad variety of repair mechanisms developed in the course of evolution that enables cells to quickly react and patch up the affected DNA strands.

11 Jun 2018

New DNA test identifies men at highest risk of prostate cancer

A major new study of more than 140,000 men has identified 63 new genetic variations in the DNA code that increase the risk of prostate cancer.

11 Jun 2018

Genetic mutation shown to cause bipolar disorder

Researchers have discovered a mutation that may increase the risk of bipolar disorder through a complex interplay between serotonin and mitochondrial signaling.

11 Jun 2018

Novel computer models for individualization of HIV therapy in countries with limited healthcare resources

New predictive computer models designed to optimize HIV therapy in countries with limited healthcare resources are published online this week in the Journal of Antimicrobial Chemotherapy.

11 Jun 2018

Alnylam announces new positive results from Phase 1/2 study of lumasiran in patients with PH1

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1.

8 Jun 2018